The result was keep. Mark Arsten ( talk) 22:23, 2 August 2012 (UTC) reply
Non-notable drug company. All the coverage appears to be either routine coverage from the financial markets or coverage focused on Torezolid, which already has an article. Stuartyeates ( talk) 23:06, 26 July 2012 (UTC) reply